Alzheimer's Disease - Prescribing trends indicate that neurologists are not adhering to guidelines

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-12-20

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

A lack of prescriber adherence to both marketing licenses and pharmacoeconomic guidelines represents both a challenge and opportunity for pharmaceutical companies marketing current Alzheimer's disease drugs. Indication expansion between disease severities may not be a viable commercial option; conversely, stricter guidelines by bodies such as the UK's NICE will not necessarily threaten the market.


Scope

  • Treatment trends of front-line Alzheimer's disease drug prescribers, based on a survey of 181 neurologists.
  • Insight into neurologist's perception of marketed and pipeline drugs according to Datamonitor's primary research.
  • Rating of unmet needs in Alzheimer's disease pharmacotherapy.
  • In-depth interviews with five key international opinion leaders.


    • Report Highlights
    Datamonitor's survey shows that symptomatic improvement is still a high priority, indicating that neurologists would welcome a new non-disease modifying drug if it was differentiated from the current cognitive enhancers on efficacy or side effects. In order to achieve this in the minds of neurologists, an alternative mode of action is required.

    Datamonitor forecasts that the introduction of disease modifying drugs (e.g. Alzhemed, Flurizan) will not necessarily threaten the acetylcholine esterase inhibitor market, in fact, treatment with such drugs will extend the therapeutic window for symptomatic drugs, resulting in an opportunity for key players in this market.

    Datamonitor believes that the recently published NICE guidelines will only have a modest impact on Alzheimer's disease drug sales in the UK. From looking at survey reported current prescribing trends and relating this to adherence with previous NICE Alzheimer's disease drug guidelines, prescribers do not appear to guideline-prescribe.


    Reasons to Purchase

  • Understand differential treatment and unmet needs in different disease severities.
  • Benchmark brand awareness and neurologists perceptions surrounding product positioning in order to formulate lifecycle management strategies.
  • Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products.

    • Table of Contents

    Other users found this report page using the following search terms: Alzheimer amyloid neurodegenerative nice guidelines criteria receiving memory enhancers dementia memantine combination alzheimers

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.